NCT04524442 2025-01-24Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsAdvanced Accelerator ApplicationsPhase 4 Completed42 enrolled 11 charts
NCT01789281 2021-06-11Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.NovartisPhase 4 Completed34 enrolled 8 charts